Novo Nordisk, a global healthcare company, agreed to acquire Inversago Pharma, a privately owned, clinical stage company, for $1bn. “The acquisition of Inversago Pharma will further strengthen our clinical development pipeline in obesity and related disorders. This promising class of medicine pioneered by the Inversago team could lead to life-changing new treatment options for those living with a serious chronic disease and, in particular, may offer alternative or complementary solutions for people living with obesity,” Martin Holst Lange, Novo Nordisk Executive Vice President.